Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues.
Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds.
Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
Vd Andreas Bhagwani berättar om Nanologica och den pågående företrädesemissionen.
NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional
chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
For more information and order information, please see our catalogue below or contact us!
The number of registered shares and votes in Nanologica AB has changed during the month of March as a result of the directed share issues resolved by the board of directors on 30 January 2026 and approved at the subsequent extraordinary general meeting on 4 March 2026 (the “Directed Issues”). The Directed Issues comprised a
Over the weekend, a minor explosion occurred in an oven at a company that shares an office and laboratory corridor with Nanologica. The sprinkler system was activated automatically, and water was spread throughout the premises. No one has been injured and Nanologica’s equipment is unharmed. The initial assessment shows that none of Nanologica’s instruments or
Nanologica AB (publ) (“Nanologica” or the “Company”) today announces the outcome of the Company’s rights issue of appx. SEK 82.5 million (the “Rights Issue”), for which the subscription period ended on 25 March 2026. The Rights Issue has been subscribed to 63.3 percent with and without the support of subscription rights, of which appx. 62.7
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
